Peptides DB
Research-centric peptide and protocol reference hub

IGF-1 LR3 (Long R3 IGF-1) record · updated 18h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 17 studiesJump to the evidenceCompare
What is IGF-1 LR3 (Long R3 IGF-1) used for?

IGF-1 LR3 is a long-acting synthetic IGF-1 analog with reduced binding-protein affinity, used as a research-grade IGF-1 receptor agonist studied for muscle and tissue growth.

How it works: IGF-1 receptor agonist

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where IGF-1 LR3 (Long R3 IGF-1) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 92 registered trials. It describes the research record, not a recommendation.

Identity
NameIGF-1 LR3 (Long R3 IGF-1)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelPreclinical
Discovered byCurated master list · 2026
Pharmacology
MechanismIGF-1 receptor agonist
RouteSubcutaneous injection
Half-life~20-30 hours
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 26, 2026. How this works →
Research stats
Total studies17
Human / animal / cellular7 / 3 / 5
Highest trial phasePreclinical
Years covered1995–2026
Latest study22d ago
Publication history
19952026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

17 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15.
FindingIGF-I receptor messenger ribonucleic acid levels were 45% and 52% of control values.
Human1995Full text read0.80
Proteolysis of insulin-like growth factor-binding protein-3 by human skin keratinocytes in culture in comparison to that in skin interstitial fluid: the role and regulation of components of the plasmin system.
FindingNot reported in abstract.
In vitro1997Full text read0.70
Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells.
FindingIGF-I stimulated baseline telomerase activity in all three cell lines, ranging from 2- to 10-fold (P < 0.05).
In vitro2003Full text read0.80
Long-anchoring Stent Method as a Rescue Technique for Early Dysfunction of Covered Self-Expandable Metal Stents in Distal Malignant Biliary Obstruction: A Retrospective Case Series.
FindingMedian angle of the SEMS significantly straightened from 128.3° to 151.5° after anchoring stent placement, p < 0.001.
Human2023Full text read0.80
Ulcerative Esophagitis With Marked Eosinophilic Infiltration and Fluorodeoxyglucose-Positron Emission Tomography Positivity Requiring Differentiation From Esophagogastric Junction Carcinoma.
Finding70 eosinophils per high-power field in biopsy specimens.
Human2023Full text read0.80
Successful Endoscopic Submucosal Dissection for Primary Esophageal Mucosa-Associated Lymphoid Tissue Lymphoma.
FindingNot reported in abstract.
Human2026Full text read0.80
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
FindingA primary-outcome event occurred in 137 patients (3.4%) in the balanced-fluid group and in 124 (3.0%) in the 0.9%-saline group.
Human2026Full text read0.90
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
TakeawayNot reported in abstract.
—2026Title only0.10
Long-term effectiveness of typhoid conjugate vaccine in Nepal.
TakeawayNot reported in abstract.
—2026Title only0.10
Glomerulus-Targeted Nanotherapy via Collagen IV-α3 Binding Enhances Renal Immunoregulation in Lupus Nephritis.
Finding30% increase in glomerular filtration rate (GFR).
Animal2026Full text read0.70
Long-Term Survival Advantage of Reoperative Surgical Mitral Valve Replacement Over Transcatheter Mitral Valve-in-Valve: A Multicenter Cohort.
Finding20.3% mortality for rSMVR vs 40.9% for mViV at 5 years, P = .01
Human2026Full text read0.80
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.
Finding0.5 g/L XynCDBFV-IGF-1 and 1 g/L XynCDBFV-LR3 IGF-1 achieved in a 15-L bioreactor.
In vitro2023Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching IGF-1 LR3 (Long R3 IGF-1) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much IGF-1 LR3 (Long R3 IGF-1) is discussed should be drawn from it.